- Galena Biopharma (GALE -14.3%) late today publicly responds to its shareholders, amplifying what were brief dismissals of Adam Feuerstein's Wednesday article on the firm and stock-promotion allegations, and calling his work "tabloid-like."
- "The only facts in Mr. Feuerstein's most recent article that are remotely accurate," writes CEO Mark Ahn, "are that Galena previously engaged the DreamTeamGroup and that insiders at the company, including me, divested shares in mid January."
- Volume of more than 40M shares today was nearly four times the company's average; after-hours shares were tracking slightly higher from the close, +0.5%.
From other sites
at CNBC.com (May 21, 2014)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Mar 17, 2014)
Video at CNBC.com (Jan 16, 2014)
at CNBC.com (Jan 16, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs